VIGL
USDVigil Neuroscience Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$7.870
Kõrge
$7.880
Madal
$7.840
Maht
3.58M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
367.3M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.10M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm
The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil Neuroscience, Inc. ...
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Stifel Downgrades Vigil Neuroscience to Hold, Lowers Price Target to $8
Stifel analyst Paul Matteis downgrades Vigil Neuroscience from Buy to Hold and lowers the price target from $11 to $8.
HC Wainwright & Co. Downgrades Vigil Neuroscience to Neutral, Lowers Price Target to $8
HC Wainwright & Co. analyst Andrew Fein downgrades Vigil Neuroscience from Buy to Neutral and lowers the price target from $14 to $8.
Seotud aktsiad
JQC
Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
YEXT
Yext Inc.
SLE
Super League Enterprise Inc.
MEGI
MainStay CBRE Global Infrastructure Megatrends Term Fund Common Shares
CSBR
Champions Oncology Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.